The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study
Chia-Huei Chu, Yi-Chao Hsu, Chang-Yin Lee, Liang-Yu Lin, Wu-Lung Chuang, Heng-Jun Lin, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang · 2025
Read The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study by Chia-Huei Chu, Yi-Chao Hsu, Chang-Yin Lee, Liang-Yu Lin, Wu-Lung Chuang, Heng-Jun Lin, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751864.txt.
Description
Chia-Huei Chu and co-authors link a class of diabetes drugs to safer hearing in this 2025 study. Hearing loss in the inner ear is a quiet complication of type 2 diabetes. The drugs in view, SGLT2 inhibitors, already protect hearts and kidneys beyond sugar control; whether they touch hearing was unknown.
From Taiwan's national insurance records the team matched users of the drugs with non-users among more than 380,000 patients. Users developed confirmed hearing loss at a lower rate, with risk about sixteen percent lower overall. The pattern held across sex, age, town size, and illness groups. Long use mattered most: a year or more of therapy came with risk cut to about a third. The authors call hearing a part of full diabetes care and suggest the drugs may guard the ear as they guard other organs.
Catalog record
| CREATOR | Chia-Huei Chu, Yi-Chao Hsu, Chang-Yin Lee, Liang-Yu Lin, Wu-Lung Chuang, Heng-Jun Lin, Cheng-Li Lin, Der-Yang Cho, Kuang-Hsi Chang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |